CCT greater in the hypertensive

Article

Greater central corneal thickness (CCT) measurements are observed in those with ocular hypertension than in those without, according to a report published online ahead of publication in Ophthalmology.

Greater central corneal thickness (CCT) measurements are observed in those with ocular hypertension than in those without, according to a report published online ahead of publication in Ophthalmology.

Researchers involved in the European Glaucoma Prevention Study Group (EGPS), conducted a randomized, double-masked, controlled, observational clinical trial of 854 of the patients enrolled in EGPS. A total of 429 patients were treated with dorzolamide and 425 received a placebo. CCT thickness was measured by ultrasound pachymetry and measurements were taken in the morning before intraocular pressure (IOP). Five measurements were taken from each eye of each patient within five minutes of application of anaesthetic eye drops.

Results showed that mean CCT was 572.6±37.4 µm (range 458.5 – 695.6 µm). CCT was higher in younger patients, male patients and diabetic patients. Mean CCT measurements for the dorzolamide patients was recorded at 574.2±38.48 µm (range 458.5 – 695.6 µm) and for the placebo patients, 571.0±36.21 µm (rage 469.7 – 690.1 µm). CCT did not correlate with refraction, baseline IOP or systemic hypertension.

The researchers found that CCT measurements for those with ocular hypertension are higher than for those without the condition.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.